Insmed INC 8-K filings

Insmed has announced the redemption of all $225 million of its outstanding 1.75% Convertible Senior Notes due in 2025, with a redemption date set for August 9, 2024.

Insmed and AstraZeneca did not reach an agreement for AstraZeneca to further develop and commercialize brensocatib for COPD and asthma, leaving Insmed with full worldwide rights outside of those indications.

Insmed hosted a commercial webinar on June 4, 2024, to discuss the market outlook for its three most advanced programs: ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP).

Insmed successfully completed a public offering of common stock, raising approximately $713.9 million to fund research and development and other corporate activities.

Insmed's Phase 3 ASPEN study of brensocatib met its primary endpoint, showing statistically significant reductions in pulmonary exacerbations for patients with non-cystic fibrosis bronchiectasis.

Insmed Incorporated's shareholders approved an amendment to the 2019 Incentive Plan and elected four Class III directors at their annual meeting on May 13, 2024.

Insmed reported a 16% increase in ARIKAYCE revenue for Q1 2024 and shared positive safety and tolerability data from its Phase 2 TPIP studies.

AstraZeneca has exercised its final option to further develop and potentially commercialize Insmed's brensocatib for chronic obstructive pulmonary disease (COPD) and asthma.

Insmed has entered into a sales agreement for up to $500 million in common stock, while also reporting its fourth-quarter and full-year 2023 financial results and providing a business update.